Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Next Previous
Trial Profile

This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Step by Step
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 09 Nov 2022 Results assessing the short-term cost-effectiveness of insulin degludec/insulin aspart versus basal plus bolus insulin in Indian setting from Step-by-step clinical trial, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 18 May 2022 Results of a cost-effectiveness analysis of insulin degludec or insulin aspart versus insulin glargine + insulin aspart for treatment of patients with type2diabetes using data from this clinical study presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 01 Jan 2019 Primary endpoint (Change from baseline in glycosylated haemoglobin (HbA1c)) has been met, according to the published in the Diabetes Research and Clinical Practice
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top